BioCentury
ARTICLE | Company News

Eutropics, Tolero Pharmaceuticals deal

November 23, 2015 8:00 AM UTC

Eutropics granted Tolero exclusive rights to use Eutropics’ Praedicare-Dx biomarker platform in the development of Tolero’s alvocidib. The companies partnered in 2014 to use platform to predict responses to Tolero’s compounds to treat hematological malignancies. The Praedicare-Dx identifies alterations in apoptosis signaling pathways in cancer cells and stratifies leukemia and myeloma patients based on the likelihood of responding to treatment. ...